

Management of osteoporosis in rheumatology day hospital : does the clinical pharmacist have a role to play?

P. RANSON (1), M. AYADI (1), O. IGHILAHRIZ (2), M. MEGNE-WABO (1), D. CHENEVIER (1). Pharmacy department, Hospital of Cognac, Cognac, France (2) Rheumatology department, Hospital of Cognac, Cognac, France.

BACKGROUND AND IMPORTANCE

A multidisciplinary day hospitalization (DH) dedicated to osteoporosis was established in our medical center in May 2023. Clinical pharmacist provides individualized care through a medication review, a medication reconciliation and a pharmaceutical consultation (PC).

AIM AND OBJECTIVES

Assessment of the pharmaceutical impact in the management of patients with osteoporosis.

Data from May 2023 to May 2024 were extracted from the electronic medical record and pharmaceutical report

Points discussed with patients during PC :

- Informations about osteoporosis
- Osteoporosis treatment (mechanism of action, side effects, precaution of use)
- Hygienic-dietary rules.

Pharmaceuticals interventions

- refered to :
 - Rheumatologist
- General practitioners (GPs)

Pharmaceuticals reports sent to :

N°4CPS-227


de grand

- GPs

-

- Community pharmacist

RESULTS





Intervention

In total, 63 pharmaceutical interventions

(Pls) were performed : 0.8 Pl per patient

- ❖ 31 PIs performed to the rheumatologist → 100% Accepted
- * 32 Pls perfomed to GPs
- 5 smoking and alcohol cessation program were scheduled





→ The one-year hospitalization rate for falls and fractures is 5.1%.

CONCLUSION AND RELEVANCE

This study highlights the positive impact of a clinical pharmacist intervention in an osteoporosis day hospital on therapeutic optimization and patients education about their disease and treatments. All PIs referred to the rheumatologist were accepted. A study is undergoing to evaluate the acceptance rate of the PIs referred to GPs.